Should I Buy GMED? GMED 2026 Analysis

Should You Buy Globus Medical Inc (GMED) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

87.810

1 Day change

0.35%

52 Week Range

101.400

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Buy now: price is sitting right on key support (S1 ~87.2; S2 ~85.0) while short-term momentum looks oversold, setting up a tradable rebound.
Sentiment tailwinds: options positioning is call-heavy (very low put-call by volume) and Wall Street has recently leaned more bullish with multiple Buy/Overweight ratings and higher targets.
Fundamentals support the dip-buy: latest reported quarter (2025/Q3) shows strong acceleration in revenue and earnings, which helps justify buying weakness rather than chasing strength.
Tactical levels: first rebound targets are the pivot (~~90.7) then R1 (~~94.2).

Technical Analysis

Trend/momentum: MACD histogram -0.939 and negatively expanding → downside momentum is still present (trend not fully healed yet).
RSI (6): 20.506 → effectively oversold/washed-out near-term conditions (often precedes bounces when price is at support).
Moving averages: converging MAs → suggests consolidation/transition phase, consistent with a potential base forming.
Key levels:
- Support: 87.215 (S1), then 85.048 (S2)
- Resistance: 90.721 (Pivot), 94.228 (R1), then 96.395 (R2)
Pattern-based forward bias (provided): next month skew is negative (-8.02% expectation) → reinforces keeping this as a support-based entry (buying near 87/85 makes more sense than chasing above pivot).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning (OI): Put/Call OI ratio 0.65 → more calls than puts outstanding, generally constructive.
Flow (volume): Put/Call volume ratio 0.08 (calls 110 vs puts 9) → strongly bullish intraday sentiment, though total volume is modest (119).
Implied volatility: 30D IV 39.77 vs historical vol 29.35 → options are pricing elevated near-term movement.
IV percentile/rank: IV percentile 66.53 (elevated vs the last year), IV rank 12.78 (not extreme vs the period used) → mildly supportive for directional trades, not a “panic peak.”

Technical Summary

Sell

Buy

Positive Catalysts

- Operational narrative improving: commentary highlights better-than-expected revenue pre-announcement and expectations for margin expansion (including Nevro-related margin tailwinds mentioned by analysts).

Neutral/Negative Catalysts

- Technical downside momentum still active: MACD is negative and expanding, so the chart hasn’t fully confirmed a trend reversal yet.
- Near-term resistance overhead: pivot around 90.7 and R1 94.2 may cap rebounds and create choppiness.
- News feed provided is generic: limited specific incremental news detail beyond “ratings adjusted,” reducing confidence in an immediate event-driven surge.
- Short-term statistical skew (provided): similar-pattern analysis indicates a negative 1-month bias (-8.02%), which argues against chasing rallies and favors buying only near support (current zone).

Financial Performance

Latest quarter provided: 2025/Q3
- Revenue: $769.0M, +22.91% YoY (strong top-line acceleration)
- Net Income: $119.0M, +129.50% YoY (profit growth materially outpacing revenue)
- EPS: $0.88, +131.58% YoY
- Gross Margin: 63.28%, up 21.76% YoY (margin expansion supports the bullish analyst angle)
Overall: growth + margin expansion signals improving operating leverage into the next print (QDEC 2025 on 2/24).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Trend (recent 2 months): clear shift more bullish with upgrades, higher targets, and new Buy initiations.
Notable changes:
- Needham (2026-01-30): Upgraded to Buy from Hold, PT $112
- TD Cowen (2026-01-26): Initiated Buy, PT $110
- Piper Sandler (2026-01-08): Overweight, PT raised to $115 from $90
- Canaccord (2026-01-09): Buy, PT to $112
- BofA (2025-12-08): Buy, PT $106
- Morgan Stanley (2025-12-02): Overweight, PT $100
- Dissenting/less bullish: Freedom Capital (2025-12-16) Hold, PT $87 (roughly in-line with current price)
Wall Street pros vs cons:
- Pros: improving revenue trajectory, expectations for organic growth improvement, margin expansion potential, long-tailed earnings power story.
- Cons: some view “solid growth already priced in” (Hold at $87), and execution is still a key debate (analysts note there’s still work to do).
Influential/political trading check: No recent congress trading data available; insider/hedge fund trend provided as Neutral (no significant recent activity).

GMED Should I Buy